Vanguard Portfolio Management’s Karyopharm Therapeutics KPTI Stock Holding History

Vanguard Portfolio Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32M	Buy	+134,818	New	+$1.17M	﹤0.01%	2878

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management's KPTI Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 134,818 shares worth $1.32M. The stake represents ﹤0.01% of the portfolio and ranks #2878 among its holdings.

96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Vanguard Portfolio Management held 134,818 shares of Karyopharm Therapeutics worth $1.32M as of Q2 2026.
Karyopharm Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
Karyopharm Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2878 holding.
96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.